Holen Sie sich die Stockscreener-App
3.20
1.27%
0.04
Vorhandelsmarkt:
3.06
-0.14
-4.38%
Schlusskurs vom Vortag:
$3.16
Offen:
$3.15
24-Stunden-Volumen:
18,246
Relative Volume:
1.95
Marktkapitalisierung:
$11.25B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-10.36%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.07
$3.30
1-Wochen-Bereich:
$3.04
$3.60
52-Wochen-Spanne:
$2.90
$3.9441
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Firmenname
Neuphoria Therapeutics Inc
Sektor
Branche
Telefon
61 8 8150 7400
Adresse
200 GREENHILL ROAD, EASTWOOD SA
Vergleichen Sie NEUP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.20 | 11.25B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.66 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.87 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.60 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.51 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.43 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Bestätigt | Maxim Group | Buy |
| 2022-01-10 | Eingeleitet | Berenberg | Buy |
| 2022-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Eingeleitet | Evercore ISI | Outperform |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Bionomics Limited Publishes the Positive Results from the Phase 2 June Study of Bnc210 in Patients with Post-Traumatic Stress Disorder in Nejm Evidence - Marketscreener.com
Bionomics Limited announced that it expects to receive $70 million in funding - Marketscreener.com
Bionomics Limited to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting - Marketscreener.com
Bionomics Limited Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder - Marketscreener.com
NEUP (Neuphoria Therapeutics) Cash From Other Investing Act - GuruFocus.com
NEUP (Neuphoria Therapeutics) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
We're Keeping An Eye On Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Rate - Yahoo Finance
Bionomics Strategic Shift with Neuphoria Redomiciliation - Yahoo Finance
Neuphoria Therapeutics More Than Doubles After Bionomics Re-Domiciliation - MarketWatch
Big Moves in Biotech! Neuphoria's Bold Transformation Unveiled! - Jomfruland.net
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - GlobeNewswire
Bionomics Secures Major Court Approval for Strategic US Market Shift, Sets December Trading Timeline - StockTitan
Results of Scheme Meeting - The Manila Times
Bionomics Limited (BNOX) Quarterly 10-Q Report - Quartz
Bionomics : Scheme Implementation Agreement – Amending Agreement Form 8 K - Marketscreener.com
Bionomics CEO believes company has ‘significant, unrealized value’ - Yahoo Finance
Apeiron entities sell Bionomics shares worth $82,526 - Investing.com
Bionomics Limited announces intention to re-domicile to the United States - GlobeNewswire
Bionomics Initiates Affirm-1, A Phase 3 Clinical Trial with Bnc210 for Social Anxiety Disorder - Marketscreener.com
Bionomics to Present at Biotech Showcase™ 2024 - Marketscreener.com
Biometrics Soar After Company Says Trial of BNC210 Meets Primary Endpoint of Decrease in Severity of Post-Traumatic Stress Disorder Symptoms - Marketscreener.com
BNOXBionomics Limited American Depository Shares Latest Stock News & Market Updates - StockTitan
Finanzdaten der Neuphoria Therapeutics Inc-Aktie (NEUP)
Es liegen keine Finanzdaten für Neuphoria Therapeutics Inc (NEUP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.13%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):